Chris joined GTCR in 2013. Prior to joining GTCR, he worked as an Investment Banking Analyst in the Mergers & Acquisitions / Corporate Finance group of Morgan Stanley. Chris graduated cum laude from the University of Notre Dame with a BBA in finance.

Chris is a Director of Antylia Scientific, PathGroup and TerSera Therapeutics, and works closely with Cedar Gate Technologies. He was previously a Director of Riverchase Dermatology and played an instrumental role in GTCR’s investments in Crealta Pharmaceuticals, Curo and Maravai Life Sciences.